Specialty Pharma Journal Specialty, Precision & Technology
CAMBRIDGE, Mass. & EMERYVILLE, Calif.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell …
Tag Archives: T cell receptors
August, 2018
-
6 August
Regeneron and bluebird bio Collaborate for Development of New Cell Therapies for Cancer
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and bluebird bio, Inc. (NASDAQ: BLUE) today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human …
July, 2018
-
19 July
Kite and Gadeta Collaborate to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors
SANTA MONICA, Calif. & UTRECHT, Netherlands–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in …
July, 2016
-
13 July
Treatment Targets HIV’s Last Hiding Place
UK scientists may have found a way to destroy HIV’s last refuge. A study by Oxford University has confirmed that a treatment developed by a British company can remove the virus in its chosen hiding place, in laboratory conditions, offering hope of a viable treatment. Professor Lucy Dorrell and her …
January, 2016
-
13 January
Juno Therapeutics Acquires AbVitro, Adding Next-Generation Single Cell Sequencing Capabilities
SEATTLE–(BUSINESS WIRE)–Jan. 11, 2016– Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced today that it has acquired AbVitro, Inc., a privately held biotechnology company based in Boston, Massachusetts. The acquisition provides Juno with a leading next-generation …